Skip to main content
AAN.com
Articles
January 9, 2006

Familial Alzheimer disease in Latinos
Interaction between APOE, stroke, and estrogen replacement

January 10, 2006 issue
66 (1) 35-40

Abstract

Background: Factors that modify risk related to APOE variants have been examined primarily in unrelated patients and controls, but seldom in family-based studies. Stroke, vascular risk factors, estrogen replacement therapy (ERT), head injury (HI), and smoking have been reported to influence risk of sporadic but not familial Alzheimer disease (AD).
Objectives: To examine the potential relationship between these risk factors and APOE, the authors used a family study design in a population in which the APOE-ε4 variant is strongly associated with risk of AD.
Methods: Latino families primarily from the Caribbean Islands in which two or more living relatives had dementia were identified in the New York City metropolitan area, the Dominican Republic, and Puerto Rico. A total of 1,498 participants from 350 families underwent a clinical interview, medical and neurologic examinations, neuropsychological testing, and APOE genotyping. Diagnosis was made by consensus using research criteria for AD.
Results: APOE-ε4 was associated with a nearly twofold increased risk of AD. A history of stroke was also associated with a fourfold increased risk. A statistical interaction between APOE-ε4 and stroke was observed. Women with an APOE-ε4 who took ERT did not have an increased risk of AD, but in women with a history of stroke ERT was a deleterious effect modifier.
Conclusions: APOE-ε4 and stroke independently increase risk of familial Alzheimer disease (AD) among Latinos, and may interact to further increase AD risk. Among women, the risk of AD associated with APOE-ε4 may be attenuated by a history of ERT.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Corder EH, Lannfelt L, Bogdanovic N, Fratiglioni L, Mori H. The role of APOE polymorphisms in late-onset dementias. Cell Mol Life Sci 1998;54:928–934.
2.
Slooter AJ, Cruts M, Kalmijn S, et al. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch Neurol 1998;55:964–968.
3.
Roses AD. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu Rev Med 1996;47:387–400.
4.
Mayeux R. Epidemiology of neurodegeneration. Annu Rev Neurosci 2003;26:81–104.
5.
Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348:429–432.
6.
Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 1997;48:1517–1521.
7.
Zandi PP, Carlson MC, Plassman BL, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA 2002;288:2123–2129.
8.
LeBlanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA 2001;285:1489–1499.
9.
Mayeux R, Ottman R, Maestre G, et al. Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. Neurology 1995;45:555–557.
10.
Katzman R, Galasko DR, Saitoh T, et al. Apolipoprotein-epsilon4 and head trauma: synergistic or additive risks? Neurology 1996;46:889–891.
11.
Merchant C, Tang MX, Albert S, Manly J, Stern Y, Mayeux R. The influence of smoking on the risk of Alzheimer's disease. Neurology 1999;52:1408–1412.
12.
Ott A, Slooter AJ, Hofman A, et al. Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study. Lancet 1998;351:1840–1843.
13.
Honig LS, Tang MX, Albert S, et al. Stroke and the risk of Alzheimer disease. Arch Neurol 2003;60:1707–1712.
14.
Breteler MM. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging 2000;21:153–160.
15.
Romas SN, Santana V, Williamson J, et al. Familial Alzheimer disease among Caribbean Hispanics: a reexamination of its association with APOE. Arch Neurol 2002;59:87–91.
16.
Maraganore DM. Blood is thicker than water: the strengths of family-based case-control studies. Neurology 2005;64:408–409.
17.
Scott WK, Zhang F, Stajich JM, Scott BL, Stacy MA, Vance JM. Family-based case-control study of cigarette smoking and Parkinson disease. Neurology 2005;64:442–447.
18.
Witte JS, Gauderman WJ, Thomas DC. Asymptotic bias and efficiency in case-control studies of candidate genes and gene-environment interactions: basic family designs. Am J Epidemiol 1999;149:693–705.
19.
Mayeux R, Ottman R, Tang MX, et al. Genetic susceptibility and head injury as risk factors for Alzheimer's disease among community-dwelling elderly persons and their first-degree relatives. Ann Neurol 1993;33:494–501.
20.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939–944.
21.
Pittman J, Andrews H, Tatemichi T, et al. Diagnosis of dementia in a heterogeneous population. A comparison of paradigm-based diagnosis and physician's diagnosis. Arch Neurol 1992;49:461–467.
22.
Stern Y, Andrews H, Pittman J, et al. Diagnosis of dementia in a heterogeneous population. Development of a neuropsychological paradigm-based diagnosis of dementia and quantified correction for the effects of education. Arch Neurol 1992;49:453–460.
23.
Devi G, Marder K, Schofield PW, Tang MX, Stern Y, Mayeux R. Validity of family history for the diagnosis of dementia among siblings of patients with late-onset Alzheimer's disease. Genet Epidemiol 1998;15:215–223.
24.
Maestre G, Ottman R, Stern Y, et al. Apolipoprotein E and Alzheimer's disease: ethnic variation in genotypic risks. Ann Neurol 1995;37:254–259.
25.
Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545–548.
26.
SAS/STAT Software. Changes and enhancements through release 6.12. Cary, NC: SAS Institute, 1998.
27.
Haan MN, Shemanski L, Jagust WJ, Manolio TA, Kuller L. The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA 1999;282:40–46.
28.
Kang JH, Logroscino G, De Vivo I, Hunter D, Grodstein F. Apolipoprotein E, cardiovascular disease and cognitive function in aging women. Neurobiol Aging 2005;26:475–484.
29.
Hofman A, Ott A, Breteler MM, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997;349:151–154.
30.
Hayden KM, Pieper CF, Welsh-Bohmer KA, Breitner JC, Norton MC, Munger R. Self- or proxy-reported stroke and the risk of Alzheimer disease. Arch Neurol 2004;61:982; author reply 983.
31.
Slooter AJ, Tang MX, van Duijn CM, et al. Apolipoprotein E epsilon4 and the risk of dementia with stroke. A population-based investigation. JAMA 1997;277:818–821.
32.
Skoog I, Hesse C, Aevarsson O, et al. A population study of apoE genotype at the age of 85: relation to dementia, cerebrovascular disease, and mortality. J Neurol Neurosurg Psychiatry 1998;64:37–43.
33.
Townsend KP, Obregon D, Quadros A, et al. Proinflammatory and vasoactive effects of Abeta in the cerebrovasculature. Ann NY Acad Sci 2002;977:65–76.
34.
Colton CA, Brown CM, Cook D, et al. APOE and the regulation of microglial nitric oxide production: a link between genetic risk and oxidative stress. Neurobiol Aging 2002;23:777–785.
35.
Baldereschi M, Di Carlo A, Lepore V, et al. Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging. Neurology 1998;50:996–1002.
36.
Waring SC, Rocca WA, Petersen RC, O'Brien PC, Tangalos EG, Kokmen E. Postmenopausal estrogen replacement therapy and risk of AD: a population-based study. Neurology 1999;52:965–970.
37.
Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med 1996;156:2213–2217.
38.
Henderson VW, Paganini-Hill A, Emanuel CK, Dunn ME, Buckwalter JG. Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol 1994;51:896–900.
39.
Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651–2662.
40.
Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291:2947–2958.
41.
Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2663–2672.
42.
Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291:2959–2968.
43.
Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology 2000;54:295–301.
44.
Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 2000;283:1007–1015.
45.
Wang PN, Liao SQ, Liu RS, et al. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology 2000;54:2061–2066.
46.
Barrett-Connor E. Postmenopausal estrogen and prevention bias. Ann Intern Med 1991;115:455–456.
47.
Marder K, Sano M. Estrogen to treat Alzheimer's disease: too little, too late? So what's a woman to do? Neurology 2000;54:2035–2037.
48.
O'Meara ES, Kukull WA, Sheppard L, et al. Head injury and risk of Alzheimer's disease by apolipoprotein E genotype. Am J Epidemiol 1997;146:373–384.
49.
Jellinger KA, Paulus W, Wrocklage C, Litvan I. Effects of closed traumatic brain injury and genetic factors on the development of Alzheimer's disease. Eur J Neurol 2001;8:707–710.
50.
Guo Z, Cupples LA, Kurz A, et al. Head injury and the risk of AD in the MIRAGE study. Neurology 2000;54:1316–1323.
51.
Botto LD, Khoury MJ. Commentary: Facing the challenge of gene-environment interaction: The two-by-four table and Beyond. Am J Epidemiol 2001;153:1016–1020.

Information & Authors

Information

Published In

Neurology®
Volume 66Number 1January 10, 2006
Pages: 35-40
PubMed: 16401842

Publication History

Published online: January 9, 2006
Published in print: January 10, 2006

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

G. A. Rippon, MD
From the Department of Neurology (G.A.R., R.M.), Gertrude H. Sergievsky Center (G.A.R., M.-X.T., J.H.L., R.M.), Taub Institute for Research on Alzheimer's Disease and the Aging Brain (G.A.R., M.-X.T., J.H.L., R.L., R.M.), and Departments of Psychiatry (R.M.) and Internal Medicine (R.L.), Columbia University College of Physicians and Surgeons, and the Department of Epidemiology (M.-X.T., J.H.L., R.M.), Mailman School of Public Health, Columbia University, New York, NY; and The Universidad Tecnologica de Santiago (M.M.), Santiago, Dominican Republic.
M. X. Tang, PhD
From the Department of Neurology (G.A.R., R.M.), Gertrude H. Sergievsky Center (G.A.R., M.-X.T., J.H.L., R.M.), Taub Institute for Research on Alzheimer's Disease and the Aging Brain (G.A.R., M.-X.T., J.H.L., R.L., R.M.), and Departments of Psychiatry (R.M.) and Internal Medicine (R.L.), Columbia University College of Physicians and Surgeons, and the Department of Epidemiology (M.-X.T., J.H.L., R.M.), Mailman School of Public Health, Columbia University, New York, NY; and The Universidad Tecnologica de Santiago (M.M.), Santiago, Dominican Republic.
J. H. Lee, DrPH
From the Department of Neurology (G.A.R., R.M.), Gertrude H. Sergievsky Center (G.A.R., M.-X.T., J.H.L., R.M.), Taub Institute for Research on Alzheimer's Disease and the Aging Brain (G.A.R., M.-X.T., J.H.L., R.L., R.M.), and Departments of Psychiatry (R.M.) and Internal Medicine (R.L.), Columbia University College of Physicians and Surgeons, and the Department of Epidemiology (M.-X.T., J.H.L., R.M.), Mailman School of Public Health, Columbia University, New York, NY; and The Universidad Tecnologica de Santiago (M.M.), Santiago, Dominican Republic.
R. Lantigua, MD
From the Department of Neurology (G.A.R., R.M.), Gertrude H. Sergievsky Center (G.A.R., M.-X.T., J.H.L., R.M.), Taub Institute for Research on Alzheimer's Disease and the Aging Brain (G.A.R., M.-X.T., J.H.L., R.L., R.M.), and Departments of Psychiatry (R.M.) and Internal Medicine (R.L.), Columbia University College of Physicians and Surgeons, and the Department of Epidemiology (M.-X.T., J.H.L., R.M.), Mailman School of Public Health, Columbia University, New York, NY; and The Universidad Tecnologica de Santiago (M.M.), Santiago, Dominican Republic.
M. Medrano, MD
From the Department of Neurology (G.A.R., R.M.), Gertrude H. Sergievsky Center (G.A.R., M.-X.T., J.H.L., R.M.), Taub Institute for Research on Alzheimer's Disease and the Aging Brain (G.A.R., M.-X.T., J.H.L., R.L., R.M.), and Departments of Psychiatry (R.M.) and Internal Medicine (R.L.), Columbia University College of Physicians and Surgeons, and the Department of Epidemiology (M.-X.T., J.H.L., R.M.), Mailman School of Public Health, Columbia University, New York, NY; and The Universidad Tecnologica de Santiago (M.M.), Santiago, Dominican Republic.
R. Mayeux, MD, MSc
From the Department of Neurology (G.A.R., R.M.), Gertrude H. Sergievsky Center (G.A.R., M.-X.T., J.H.L., R.M.), Taub Institute for Research on Alzheimer's Disease and the Aging Brain (G.A.R., M.-X.T., J.H.L., R.L., R.M.), and Departments of Psychiatry (R.M.) and Internal Medicine (R.L.), Columbia University College of Physicians and Surgeons, and the Department of Epidemiology (M.-X.T., J.H.L., R.M.), Mailman School of Public Health, Columbia University, New York, NY; and The Universidad Tecnologica de Santiago (M.M.), Santiago, Dominican Republic.

Notes

Address correspondence and reprint requests to Dr. Richard Mayeux, Gertrude H. Sergievsky Center, PH19, Columbia University Medical School, 630 W. 168th Street, New York, NY 10032; e-mail: [email protected]

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Ectopic pregnancy, its potential links to dementia risk and interactions with depression: insights from a nationwide cohort study, Frontiers in Psychiatry, 15, (2024).https://doi.org/10.3389/fpsyt.2024.1410685
    Crossref
  2. Is Hormone Replacement Therapy a Risk Factor or a Therapeutic Option for Alzheimer’s Disease?, International Journal of Molecular Sciences, 24, 4, (3205), (2023).https://doi.org/10.3390/ijms24043205
    Crossref
  3. Systematic review and meta-analysis of the effects of menopause hormone therapy on risk of Alzheimer’s disease and dementia, Frontiers in Aging Neuroscience, 15, (2023).https://doi.org/10.3389/fnagi.2023.1260427
    Crossref
  4. Systematic Review, Meta-Analysis, and Population Attributable Risk of Dementia Associated with Traumatic Brain Injury in Civilians and Veterans, Journal of Neurotrauma, 40, 7-8, (620-634), (2023).https://doi.org/10.1089/neu.2022.0041
    Crossref
  5. Associations of Sex, Race, and Apolipoprotein E Alleles With Multiple Domains of Cognition Among Older Adults, JAMA Neurology, 80, 9, (929), (2023).https://doi.org/10.1001/jamaneurol.2023.2169
    Crossref
  6. Diabetes/Dementia in Sub-Saharian Africa and Nigerian Women in the Eye of Storm, Current Alzheimer Research, 19, 2, (161-170), (2022).https://doi.org/10.2174/1567205018666211116093747
    Crossref
  7. Role of estrogen in women's Alzheimer's disease risk as modified by APOE , Journal of Neuroendocrinology, 35, 2, (2022).https://doi.org/10.1111/jne.13209
    Crossref
  8. Factors Influencing Alzheimer’s Disease Risk: Whether and How They are Related to the APOE Genotype, Neuroscience Bulletin, 38, 7, (809-819), (2022).https://doi.org/10.1007/s12264-021-00814-5
    Crossref
  9. Genetic Risk Factors for Alzheimer's Disease in Racial/Ethnic Minority Populations in the U.S.: A Scoping Review, Frontiers in Public Health, 9, (2021).https://doi.org/10.3389/fpubh.2021.784958
    Crossref
  10. Vascular mild cognitive impairment and its relationship to hemoglobin A1c levels and apolipoprotein E genotypes in the Dominican Republic, Dementia & Neuropsychologia, 15, 1, (69-78), (2021).https://doi.org/10.1590/1980-57642021dn15-010007
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Figures

Tables

Media

Share

Share

Share article link

Share